Adma Biologics Inc (NASDAQ:ADMA) shares, rose in value, with the stock price up by 1.75% to the previous day’s close as strong demand from buyers drove the stock to $6.39.
Actively observing the price movement in the last trading, the stock closed the session at $6.28. The value of beta (5-year monthly) was 0.43. Referring to stock’s 52-week performance, its high was $6.76, and the low was $3.06. On the whole, ADMA has fluctuated by 4.41% over the past month.
With the market capitalization of Adma Biologics Inc currently standing at about $1.46 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 08, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.05, which is expected to increase to $0.08 for fiscal year $0.3 and then to about $0.5 by fiscal year 2025. Data indicates that the EPS growth is expected to be 330.80% in 2025, while the next year’s EPS growth is forecast to be 66.70%.
Analysts have estimated the company’s revenue for the quarter at $77.27 million, with a low estimate of $76 million and a high estimate of $79.7 million. According to the average forecast, sales growth in current quarter could jump up 35.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $333.87 million, representing an increase of 29.30% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ADMA’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ADMA currently trading nearly 1.48% and 11.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 58.34, while the 7-day volatility ratio is showing 3.06% which for the 30-day chart, stands at 3.55%. Furthermore, Adma Biologics Inc (ADMA)’s beta value is 0.44, and its average true range (ATR) is 0.23.
A comparison of Adma Biologics Inc (ADMA) with its peers suggests the former has fared considerably weaker in the market. ADMA showed an intraday change of 1.75% in last session, and over the past year, it grew by 98.45%%.
Data on historical trading for Adma Biologics Inc (NASDAQ:ADMA) indicates that the trading volumes over the past 10 days have averaged 2.65 million and over the past 3 months, they’ve averaged 2.78 million. According to company’s latest data on outstanding shares, there are 226.06 million shares outstanding.
Nearly 3.73% of Adma Biologics Inc’s shares belong to company insiders and institutional investors own 74.29% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.99 million shares as on Mar 15, 2024, resulting in a short ratio of 2.51. According to the data, the short interest in Adma Biologics Inc (ADMA) stood at 3.50% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 6.15 million. The stock has risen by 41.37% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADMA stock heading into the next quarter.
